Balyasny Asset Management L.P. lifted its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 781.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 103,850 shares of the company's stock after purchasing an additional 92,071 shares during the period. Balyasny Asset Management L.P.'s holdings in Dr. Reddy's Laboratories were worth $1,640,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently modified their holdings of RDY. Robeco Institutional Asset Management B.V. increased its stake in shares of Dr. Reddy's Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Renaissance Technologies LLC grew its stake in Dr. Reddy's Laboratories by 382.9% during the fourth quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock valued at $148,717,000 after acquiring an additional 7,467,979 shares in the last quarter. Aikya Investment Management Ltd grew its stake in Dr. Reddy's Laboratories by 416.1% during the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after acquiring an additional 4,523,303 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Dr. Reddy's Laboratories by 405.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock valued at $84,643,000 after acquiring an additional 4,301,212 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Dr. Reddy's Laboratories by 397.2% during the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after acquiring an additional 3,911,404 shares in the last quarter. 3.85% of the stock is owned by hedge funds and other institutional investors.
Dr. Reddy's Laboratories Trading Up 0.3%
Shares of RDY stock traded up $0.05 during trading hours on Friday, reaching $14.44. 1,085,237 shares of the stock were exchanged, compared to its average volume of 1,491,451. Dr. Reddy's Laboratories Limited has a 12-month low of $12.26 and a 12-month high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company's 50-day moving average price is $13.43 and its 200-day moving average price is $14.03. The firm has a market capitalization of $12.05 billion, a price-to-earnings ratio of 22.99 and a beta of 0.33.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The company had revenue of $996.17 million during the quarter, compared to analyst estimates of $83.70 billion. As a group, equities analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th.
Check Out Our Latest Analysis on RDY
Dr. Reddy's Laboratories Company Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Stories
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
